Investors who lost money with shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) should contact the Shareholders Foundation in connection with Lawsuit

An investor, who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA), filed a lawsuit over alleged violations of Federal Securities Laws by Intellia Therapeutics, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and for certain investors are short and strict deadlines running. Deadline: April 14, 2025. NASDAQ: NTLA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Cambridge, MA based Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. On July 30, 2024, Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced the authorization of its Clinical Trial Application by the United Kingdom's Medicine and Healthcare products Regulatory Agency to initiate a Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency-associated lung disease.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) reported that its annual Total Revenue rose from $36.27 million in 2023 to $57.87 million in 2024, and that its Net Loss increased from $481.09 million in 2023 to $519.02 million in 2024.

On January 9, 2025, Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced a company reorganization, disclosing that Intellia Therapeutics, Inc. "made a difficult decision to focus our resources predominantly on NTLA-2002 and nex-z where we have the greatest opportunity to create significant, near-term value," and "[p]ipeline priorities result in NTLA-3001 discontinuation and select, research-focused investment."

Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) declined from over $28 per share in July 2024 to as low as $8.96 per share on February 12, 2025.

The plaintiff claims that between July 30, 2024 to January 8, 2025, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001's development and eventual marketing, if approved, that Intellia's optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for Intellia because viral-based editing programs remained expensive and inefficient in comparison to then-existing non-viral delivery methods, that Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug's research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs, and that even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and poor mitigators of adverse effects in patients.

Those who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.